Immunocore Holdings plc IMCR
Immunocore Holdings plc (Nasdaq: IMCR) is an oncology drug developer. Its lead program, KIMMTRAK (tebentafusp), is in Phase 3 for unresectable or metastatic uveal melanoma. Its next catalyst on record is IMC-U120AI: CTA or IND submission (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IMC-U120AI — CTA or IND submission (H2 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KIMMTRAK (tebentafusp) | metastatic uveal melanoma | biologic-other | Approved |
| tebentafusp (TEBE-AM) | previously treated advanced cutaneous melanoma | biologic-other | Phase 3 |
| tebentafusp (ATOM) | adjuvant uveal melanoma | biologic-other | Phase 3 |
| brenetafusp (PRISM-MEL-301) | first-line advanced cutaneous melanoma | biologic-other | Phase 3 |
| brenetafusp (PRAME-101) | multiple PRAME-positive tumor types | biologic-other | Phase 1 |
| IMC-R117C (PIWIL-1) | advanced solid tumors incl. colorectal cancer | biologic-other | Phase 1 |
| IMC-P115C (PRAME-HLE-A02) | PRAME-expressing tumors | biologic-other | Phase 1 |
| IMC-M113V | HIV functional cure | biologic-other | Phase 1 |
| IMC-S118AI | type 1 diabetes | biologic-other | Pre-clinical |
| IMC-U120AI | autoimmune disease | biologic-other | Pre-clinical |
Recent results and decisions
- Nov 6, 2026positive Combination of KIMMTRAK and brenetafusp in first-line metastatic uveal melanoma showed 29% ORR with 70% two-year OS rate and manageable safety profile.
Across the 17 evaluable first-line patients who received the combination, ORR was 29%, mDoR was 24.1 months, mPFS was 8.1 months, and median OS was not yet reached with 29 months of follow-up and 10 patients still on study.
Filing - Nov 6, 2026started First person with type 1 diabetes dosed in Phase 1 trial of IMC-S118AI, the Company's first tissue-specific autoimmune candidate.
The Company recently announced that the first person with type 1 diabetes has been dosed in the Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate.
Filing - Sep 14, 2026completed enrollment TEBE-AM Phase 3 reached its target enrollment of 540 patients; primary endpoint is overall survival.
today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297).
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.